Mirum Pharmaceuticals (MIRM) Notes Payables (2020 - 2023)

Mirum Pharmaceuticals' Notes Payables history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2023.

• On a quarterly basis, Notes Payables fell 45.39% year-over-year to $1.1 million in Q1 2023; TTM through Mar 2023 was $1.1 million, a 45.39% decrease from a year earlier, with the FY2022 full-year figure at $1.1 million, down 45.39% from the prior year.
• Notes Payables held at $1.1 million in Q1 2023 per MIRM's latest filing, from $1.1 million in the prior quarter.
• Across five years, Notes Payables topped out at $2.2 million in Q2 2021 and bottomed at $847000.0 in Q3 2021.
• The 4-year median for Notes Payables is $1.5 million (2020), against an average of $1.5 million.
• Biggest YoY gain for Notes Payables was 114.62% in 2022; the steepest drop was 45.39% in 2022.
• Year by year, Notes Payables stood at $1.3 million in 2020, then surged by 57.91% to $2.0 million in 2021, then slumped by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
• Per Business Quant, the three latest MIRM Notes Payables figures stand at $1.1 million (Q1 2023), $1.1 million (Q4 2022), and $1.8 million (Q3 2022).